SLC5A2 and cancer: These effects underscore the pleiotropic benefits of SGLT2 inhibitors, which extend beyond their well-established cardiorenal protective roles to encompass the modulation of hematopoiesis, providing a novel therapeutic approach in the management of anemia in cancer patients [67].